FDA Approves First Treatment for Rare Blood Cancer

Today's blog features the FDA announcement regarding the first treatment for a rare blood cancer. Certain adults patients with Erdheim-Chester Disease can now be treated with Vemurafenib. This therapy is a kinase inhibitor that works by blocking certain enzymes that promote cell growth.

To learn more on this drug, please read the full article HERE!

Performance Pharmacy Solutions (PPS) is a unique pharmacy benefit procurement platform developed by HORIZON Health Ventures to efficiently and effectively place, manage and oversee our self-funded client's pharmacy benefit management programs. The PPS platform provides turnkey solutions with proven market-leading PBM partners that offer, on average, 10-15% savings.